233 related articles for article (PubMed ID: 34867864)
1. Acidic Microenvironment Determines Antibiotic Susceptibility and Biofilm Formation of
Lin Q; Pilewski JM; Di YP
Front Microbiol; 2021; 12():747834. PubMed ID: 34867864
[No Abstract] [Full Text] [Related]
2. Interplay between biofilm microenvironment and pathogenicity of
Guillaume O; Butnarasu C; Visentin S; Reimhult E
Biofilm; 2022 Dec; 4():100089. PubMed ID: 36324525
[No Abstract] [Full Text] [Related]
3. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection.
Staudinger BJ; Muller JF; Halldórsson S; Boles B; Angermeyer A; Nguyen D; Rosen H; Baldursson O; Gottfreðsson M; Guðmundsson GH; Singh PK
Am J Respir Crit Care Med; 2014 Apr; 189(7):812-24. PubMed ID: 24467627
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
Price KE; Naimie AA; Griffin EF; Bay C; O'Toole GA
J Bacteriol; 2016 Jan; 198(2):237-47. PubMed ID: 26483523
[TBL] [Abstract][Full Text] [Related]
5.
Orazi G; O'Toole GA
mBio; 2017 Jul; 8(4):. PubMed ID: 28720732
[TBL] [Abstract][Full Text] [Related]
6. Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa.
Twomey KB; O'Connell OJ; McCarthy Y; Dow JM; O'Toole GA; Plant BJ; Ryan RP
ISME J; 2012 May; 6(5):939-50. PubMed ID: 22134647
[TBL] [Abstract][Full Text] [Related]
7. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.
Stotland PK; Radzioch D; Stevenson MM
Pediatr Pulmonol; 2000 Nov; 30(5):413-24. PubMed ID: 11064433
[TBL] [Abstract][Full Text] [Related]
8. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and Genotypic Adaptations in Pseudomonas aeruginosa Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy.
Oakley JL; Weiser R; Powell LC; Forton J; Mahenthiralingam E; Rye PD; Hill KE; Thomas DW; Pritchard MF
mSphere; 2021 Jan; 6(1):. PubMed ID: 33472983
[TBL] [Abstract][Full Text] [Related]
10. Effect of Shear Stress on Pseudomonas aeruginosa Isolated from the Cystic Fibrosis Lung.
Dingemans J; Monsieurs P; Yu SH; Crabbé A; Förstner KU; Malfroot A; Cornelis P; Van Houdt R
mBio; 2016 Aug; 7(4):. PubMed ID: 27486191
[TBL] [Abstract][Full Text] [Related]
11. Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients.
Fricks-Lima J; Hendrickson CM; Allgaier M; Zhuo H; Wiener-Kronish JP; Lynch SV; Yang K
Int J Antimicrob Agents; 2011 Apr; 37(4):309-15. PubMed ID: 21382698
[TBL] [Abstract][Full Text] [Related]
12. A Shaving Proteomic Approach to Unveil Surface Proteins Modulation of Multi-Drug Resistant
Montemari AL; Marzano V; Essa N; Levi Mortera S; Rossitto M; Gardini S; Selan L; Vrenna G; Onetti Muda A; Putignani L; Fiscarelli EV
Front Med (Lausanne); 2022; 9():818669. PubMed ID: 35355602
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity.
Hendricks MR; Lashua LP; Fischer DK; Flitter BA; Eichinger KM; Durbin JE; Sarkar SN; Coyne CB; Empey KM; Bomberger JM
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1642-7. PubMed ID: 26729873
[TBL] [Abstract][Full Text] [Related]
15. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V
Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772
[TBL] [Abstract][Full Text] [Related]
16. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
Sousa AM; Monteiro R; Pereira MO
Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
[TBL] [Abstract][Full Text] [Related]
17. Acute intratracheal Pseudomonas aeruginosa infection in cystic fibrosis mice is age-independent.
Munder A; Wölbeling F; Kerber-Momot T; Wedekind D; Baumann U; Gulbins E; Tümmler B
Respir Res; 2011 Nov; 12(1):148. PubMed ID: 22059807
[TBL] [Abstract][Full Text] [Related]
18. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells.
Lashua LP; Melvin JA; Deslouches B; Pilewski JM; Montelaro RC; Bomberger JM
J Antimicrob Chemother; 2016 Aug; 71(8):2200-7. PubMed ID: 27231279
[TBL] [Abstract][Full Text] [Related]
19. Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells.
Parker D; Cohen TS; Alhede M; Harfenist BS; Martin FJ; Prince A
Am J Respir Cell Mol Biol; 2012 Jan; 46(1):6-13. PubMed ID: 21778412
[TBL] [Abstract][Full Text] [Related]
20. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
Moriarty TF; Elborn JS; Tunney MM
Br J Biomed Sci; 2007; 64(3):101-4. PubMed ID: 17910277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
